Cargando…

Clinical development of imatinib: an anticancer drug

BACKGROUND: A novel and accurate high-throughput tandem mass spectroscopic method has been developed and validated for determination of imatinib, a protein-tyrosine kinase inhibitor against chronic myeloid leukemia. MATERIALS & METHODS: Chromatographic separation was carried on XTerra(®) RP18 co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goswami, Dipanjan, Gurule, Sanjay, Lahiry, Abhiroop, Anand, Amit, Khuroo, Arshad, Monif, Tausif
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137965/ https://www.ncbi.nlm.nih.gov/pubmed/28031942 http://dx.doi.org/10.4155/fso.15.92

Ejemplares similares

Liquid chromatography–tandem mass spectrometry method for the estimation of adefovir in human plasma: Application to a pharmacokinetic study
por: Goswami, Dipanjan, et al.
Publicado: (2015)

Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/(–) electrospray tandem mass spectrometry
por: Partani, Pankaj, et al.
Publicado: (2014)

Liquid chromatography tandem mass spectrometry method for the estimation of lamotrigine in human plasma: Application to a pharmacokinetic study
por: Ghatol, Santosh, et al.
Publicado: (2013)

Development and Validation of a LC-MS/MS Method for the Simultaneous Estimation of Amlodipine and Valsartan in Human Plasma: Application to a Bioequivalence Study
por: Jangala, Hemanth, et al.
Publicado: (2014)

A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets
por: Arora, Rachna, et al.
Publicado: (2016)

Magnetite graphene oxide-albumin conjugate: carrier for the imatinib anticancer drug
por: Mashreghi, Maral, et al.
Publicado: (2023)

Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications
por: Sobierajska, Paulina, et al.
Publicado: (2020)

Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib
por: Pantazi, Despoina, et al.
Publicado: (2019)

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity
por: Marslin, Gregory, et al.
Publicado: (2015)

Transmission of Hepatitis E Virus in Developing Countries
por: Khuroo, Mohammad S., et al.
Publicado: (2016)

Therapeutic drug monitoring of imatinib
por: Wallemacq, Pierre
Publicado: (2011)

Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance
por: Carew, Jennifer S, et al.
Publicado: (2008)

Drug–drug interactions with imatinib: An observational study
por: Récoché, Isabelle, et al.
Publicado: (2016)

Anticancer Drug Development
por: Loadman, P
Publicado: (2002)

Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo
por: Lin, Qianmeng, et al.
Publicado: (2019)

Combined Treatment with Anticancer Vaccine Using Genetically Modified Endothelial Cells and Imatinib in Bladder Cancer
por: Ha, Seung Beom, et al.
Publicado: (2011)

Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
por: Hompland, Ivar, et al.
Publicado: (2016)

Diffuse duodenal nodular lymphoid hyperplasia: a large cohort of patients etiologically related to Helicobacter pylori infection
por: Khuroo, Mehnaaz S, et al.
Publicado: (2011)

Lichenoid drug eruption due to imatinib mesylate
por: Bhatia, Anuradha, et al.
Publicado: (2015)

Handbook of Anticancer Drug Development
por: Subramanian, B
Publicado: (2004)

Antiproliferative Potential of Gloriosine: A Lead for Anticancer Drug Development
por: Goel, Bharat, et al.
Publicado: (2022)

Rectal perforation due to a lost toothbrush
por: Rashid, Arshad, et al.
Publicado: (2013)

Lipid Nanocapsules for Imatinib Delivery: Design, Optimization and Evaluation of Anticancer Activity Against Melanoma Cell Line
por: Molaahmadi, Mohammad Reza, et al.
Publicado: (2019)

Clinical anticancer drug development: targeting the cyclin-dependent kinases
por: Benson, C, et al.
Publicado: (2005)

Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval
por: Selwood, D
Publicado: (2004)

Anticancer drug development: preclinical screening, clinical trials and approval
por: Teicher, B A, et al.
Publicado: (2004)

Digital clinical trial: A new norm in clinical research
por: Thakur, Sayanta, et al.
Publicado: (2021)

Diagnostic Accuracy of Point-of-Care Tests for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis
por: Khuroo, Mehnaaz Sultan, et al.
Publicado: (2015)

Lead Phytochemicals for Anticancer Drug Development
por: Singh, Sukhdev, et al.
Publicado: (2016)

Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias
por: Kang, Yunyi, et al.
Publicado: (2014)

The Effect of Apigenin on Pharmacokinetics of Imatinib and Its Metabolite N-Desmethyl Imatinib in Rats
por: Liu, Xian-yun, et al.
Publicado: (2013)

COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
por: Khuroo, Mohammad S., et al.
Publicado: (2020)

Therapeutic drug monitoring for imatinib: Current status and Indian experience
por: Arora, Brijesh, et al.
Publicado: (2013)

QTc prolongation assessment in anticancer drug development: clinical and methodological issues
por: Curigliano, G, et al.
Publicado: (2009)

The pharmacogenetics of imatinib
por: Dulucq, Stéphanie, et al.
Publicado: (2010)

Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems
por: Gyanani, Vijay, et al.
Publicado: (2021)

Anticancer Alkaloids from Trees: Development into Drugs
por: Isah, Tasiu
Publicado: (2016)

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
por: Kumar, Rajiv, et al.
Publicado: (2017)

AMP-activated protein kinase promotes breast cancer stemness and drug resistance
por: Andugulapati, Sai Balaji, et al.
Publicado: (2022)

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
por: Zhuang, Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gqs29hkjk1r7ll543dk17ggh9c